Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (31)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bray, B. J.
Right arrow Articles by Rosengren, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bray, B. J.
Right arrow Articles by Rosengren, R. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 66, 27-33 (2002)
Copyright © 2002 by the Society of Toxicology


BIOTRANSFORMATION AND TOXICOKINETICS

St. John's Wort Extract Induces CYP3A and CYP2E1 in the Swiss Webster Mouse

B. J. Bray*, N. B. Perry{dagger}, D. B. Menkes{ddagger} and R. J. Rosengren*,1

* Department of Pharmacology and Toxicology, Adams Building Room 238, Great King St., University of Otago Medical School, Dunedin, New Zealand; {dagger} New Zealand Institute for Crop and Food Research Ltd. and {ddagger} Department of Psychological Medicine, University of Otago, Dunedin, New Zealand

This investigation was designed to determine the ability of St. John's wort (SJW), a readily available antidepressant, to induce various hepatic drug metabolizing enzymes. SJW (140 or 280 mg/kg/day) was administered to male Swiss Webster mice for 1, 2, or 3 weeks. Enzymatic activity was analyzed in hepatic microsomes for all of the following drug metabolizing enzymes: CYP3A, CYP1A, CYP2E1, and UDP-glucuronosyltransferase (UDPGT). The catalytic activity of CYP1A was unchanged from control following any dose or duration of SJW, while both CYP3A and CYP2E1 catalytic activities were increased 2-fold by both SJW concentrations but only following 3 weeks of administration. Results from Western immunoblotting studies supported the changes in catalytic activity, as protein levels for CYP2E1 and CYP3A were increased (2.5-fold and 6-fold, respectively) following 3 weeks of SJW administration. Additionally, the catalytic activity of the conjugation enzyme UDPGT was unchanged from control following all SJW treatments. These results indicate that in the mouse moderate doses of SJW cause an increase in the catalytic activity and polypeptide levels of CYP2E1 and CYP3A but only following 21 days of administration, while the catalytic activity of CYP1A and UDPGT activity remain unaffected.

Key Words: St. John's wort; UDPGT; CYP3A; CYP2E1; CYP1A.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Integr Cancer TherHome page
S. S. Shord, K. Shah, and A. Lukose
Drug--Botanical Interactions: A Review of the Laboratory, Animal, and Human Data for 8 Common Botanicals
Integr Cancer Ther, September 1, 2009; 8(3): 208 - 227.
[Abstract] [PDF]


Home page
J. Leukoc. Biol.Home page
J. Haorah, B. Knipe, J. Leibhart, A. Ghorpade, and Y. Persidsky
Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction
J. Leukoc. Biol., December 1, 2005; 78(6): 1223 - 1232.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Sparreboom, M. C. Cox, M. R. Acharya, and W. D. Figg
Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
J. Clin. Oncol., June 15, 2004; 22(12): 2489 - 2503.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
S. Zhou, E. Chan, S.-Q. Pan, M. Huang, and E. J. D. Lee
Pharmacokinetic Interactions of Drugs with St John's Wort
J Psychopharmacol, June 1, 2004; 18(2): 262 - 276.
[Abstract] [PDF]


Home page
Pharmacol. Rev.Home page
L. G. Costa, L. Steardo, and V. Cuomo
Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects
Pharmacol. Rev., March 1, 2004; 56(1): 103 - 147.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. G. Goodin and R. J. Rosengren
Epigallocatechin Gallate Modulates CYP450 Isoforms in the Female Swiss-Webster Mouse
Toxicol. Sci., December 1, 2003; 76(2): 262 - 270.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
L. Cantoni, M. Rozio, A. Mangolini, L. Hauri, and S. Caccia
Hyperforin Contributes to the Hepatic CYP3A-Inducing Effect of Hypericum perforatum Extract in the Mouse
Toxicol. Sci., September 1, 2003; 75(1): 25 - 30.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
P. Hammerness, E. Basch, C. Ulbricht, E.-P. Barrette, I. Foppa, S. Basch, S. Bent, H. Boon, and E. Ernst
St. John's Wort: A Systematic Review of Adverse Effects and Drug Interactions for the Consultation Psychiatrist
Psychosomatics, August 1, 2003; 44(4): 271 - 282.
[Abstract] [Full Text] [PDF]


Home page
Hum Exp ToxicolHome page
M J Le Nedelec and R J Rosengren
Methylphenidate inhibits cytochrome P450 in the Swiss Webster mouse
Human and Experimental Toxicology, May 1, 2002; 21(5): 273 - 280.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.